Nathalie Labarriere

This inventor holds 5 USPTO granted patents and 4 EPO patents. Top assignees: National Institute of Health and Medical Research, The University of Nantes, Centre National De La Recherche Scientifique. Active years: 2013-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nathalie Labarriere. Retrieved from https://idiyas.com/inventor/nathalie-labarriere

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 20.0

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Nantes Cedex 1, FR (2013)
Nantes Cedex, FR (2015)
Nantes, FR (2013 - 2017)

Company Filing History:

5 out of 1,853

National Institute of Health and Medical Research

patents

3 out of 156

The University of Nantes

patents

2 out of 5,383

Centre National De La Recherche Scientifique

where one patent can have more than one assignee

Years Active: 2013-2017

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9573975 - Melanoma antigen peptide and uses thereof (2017-02-21),

2. 9475841 - Melanoma antigen peptide and uses thereof (2016-10-25),

3. 8975371 - Melanoma antigen peptide and uses thereof (2015-03-10),

4. 8604166 - Melanoma antigen peptide and uses thereof (2013-12-10),

5. 8431394 - Antibody or fragment thereof recognizing Avitag™ and uses thereof (2013-04-30),

Title: Nathalie Labarriere: Innovator in Melanoma Research

Introduction

Nathalie Labarriere is a prominent inventor based in Nantes, France. She has made significant contributions to the field of melanoma research, particularly through her innovative work on melanoma antigen peptides. With a total of five patents to her name, Labarriere is recognized for her dedication to advancing medical science.

Latest Patents

Among her latest patents is a melanoma antigen peptide that comprises specific amino acid sequences, including SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, or function-conservative variants thereof. This invention is aimed at the prevention and treatment of melanoma in patients. Another notable patent involves a similar melanoma antigen peptide with sequences SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, also intended for melanoma prevention and treatment.

Career Highlights

Labarriere has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Nantes. Her career reflects a strong commitment to research and innovation in the medical field, particularly in oncology.

Collaborations

Some of her notable coworkers include Mathilde Bobinet and Anne Rogel, who have collaborated with her on various research projects.

Conclusion

Nathalie Labarriere's contributions to melanoma research through her patents and collaborations highlight her role as an influential inventor in the medical community. Her work continues to pave the way for advancements in the treatment of melanoma.

Profile summary based on public USPTO records.